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Abstract
Purpose: To evaluate CD4+CD25+FOXP3+ T regulatory cells (TREG) and associated immune-regulatory pathways in peripheral
blood lymphocytes (PBL) of metastatic renal cell carcinoma (mRCC) patients and healthy volunteers. We subsequently
investigated the effects of immunotherapy on circulating TREG combining an extensive phenotype examination, DNA
methylation analysis and global transcriptome analysis.
Design: Eighteen patients with mRCC and twelve volunteers (controls) were available for analysis. TREG phenotype was
examined using flow cytometry (FCM). TREG were also quantified by analyzing the epigenetic status of the FOXP3 locus
using methylation specific PCR. As a third approach, RNA of the PBL was hybridized to Affymetrix GeneChip Human Gene
1.0 ST Arrays and the gene signatures were explored using pathway analysis.
Results: We observed higher numbers of TREG in pre-treatment PBL of mRCC patients compared to controls. A significant
increase in TREG was detected in all mRCC patients after the two cycles of immunotherapy. The expansion of TREG was
significantly higher in non-responders than in responding patients. Methylation specific PCR confirmed the FCM data and
circumvented the variability and subjectivity of the FCM method. Gene Set Enrichment Analysis (GSEA) of the microarray
data showed significant enrichment of FOXP3 target genes, CTLA-4 and TGF-ß associated pathways in the patient cohort.
Conclusion: Immune monitoring of the peripheral blood and tumor tissue is important for a wide range of diseases and
treatment strategies. Adoption of methodology for quantifying TREG with the least variability and subjectivity will enhance
the ability to compare and interpret findings across studies.
Citation: Schwarzer A, Wolf B, Fisher JL, Schwaab T, Olek S, et al. (2012) Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC)
Patients Undergoing DC-Vaccination and Cytokine-Therapy. PLoS ONE 7(10): e46600. doi:10.1371/journal.pone.0046600
Editor: Yoshihiko Hoshino, National Institute of Infectious Diseases, Japan
Received April 20, 2012; Accepted September 3, 2012; Published October 31, 2012
Copyright:  2012 Schwarzer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the NIH (RO1 CA095648, P20RR016437, P20GM103413, P30CA023108 and P42ES007373) and Berlex, Inc. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Sven Olek and Udo Baron work at Epiontis who did contract testing for this study under a collaborative agreement. The authors received
funding from Berlex, Inc. for the clinical trial (Protocol D0238) from which patient samples reported on in this paper originated. This does not alter the authors’
adherence to all PLOS ONE policies on sharing data and materials.
* E-mail: Marc.S.Ernstoff@Hitchcock.ORG
. These authors contributed equally to this work.
Introduction
Although therapies with multi-targeted receptor tyrosine kinase
or mTOR inhibitors or agents which block VEGF have made
significant inroads in treatment of patients with mRCC, IL-2
therapy remains the only treatment that results in unmaintained
sustained complete remissions, albeit in a small percentage of
patients [1,2,3,4]. It is therefore important to identify biomarkers
which would allow assessment of the probability for patients to
benefit from IL-2 therapy. Increasing evidence suggests that
immune regulatory pathways, especially regulatory T-cells are the
key in limiting the benefits from IL-2 based immunotherapy
[5,6,7,8].
We previously reported a study of 18 patients with mRCC who
received intranodal vaccination with DCvacc in combination with
intravenous high-dose IL-2 and subcutaneous IFN-a2a [9]. With
this regimen we observed a surprisingly high objective response
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rate of 44% (3 complete responses, 5 partial responses, median
time to progression of 8 months). In this study we seek to better
define the circulating TREG population and associated pathways in
these mRCC patients using FCM, methylation specific PCR and
whole genome transcriptome analysis.
Naturally occurring CD4+CD25+ FOXP3+ regulatory T-cells
(nTREG) are a subpopulation of CD4 T-cells capable of
suppressing the activation and expansion of T-effector cells,
thereby inhibiting the onset of autoimmunity [10]. TREG are
characterized by constitutive expression of the IL-2R a-chain
(CD25), GITR, CTLA-4, IL-10 and TGF-ß [11,12]. FOXP3, a
member of the forkhead-family of transcription factors is the
master regulator of TREG development and function [13,14,15].
Loss of FoxP3 leads to functionally deficient TREG and causes fatal
autoimmunity [16]. Tumors often induce the expansion of TREG
cells and recruit them to the tumor site via soluble factors such as
IL10, TGF-ß and VEGF [17]. Hence, cancer patients have
significantly more TREG in their blood than healthy humans and
show infiltration of the tumor with TREG [18,19,20]. IL-2 was
initially described as T-cell growth factor and as a consequence
used in immunotherapy of RCC and melanoma. However, it has
recently been shown that IL-2 therapy substantially expands the
number of TREG in cancer patients [18,21,22]. Some studies,
including ours, suggest that non-responding patients show a higher
expansion of TREG following IL-2 based immunotherapy [23]. IL-
2 signalling induces the expression of FOXP3 in CD4+CD25+ cells
through binding of phosphorylated STAT5 to the FOXP3
proximal promoter and intron enhancers [22]. Thus, IL-2 is a
crucial factor for the development and maintenance of TREG in
the periphery [24]. How the tolerance inducing capacity of IL-2
can be reconciled with the anti-tumor effects in 15–25% of
patients with mRCC and melanoma remains elusive.
Recently published data shows that FOXP3 and CD25 are not
TREG-only specific markers. Although new markers are continuing
to be found and better gating strategies are proposed (e.g.
CD127low/2) [25], a clear and concise definition of a FCM-
staining panel defining ‘‘true’’ human TREG is still elusive. In
addition, FOXP3 is transiently upregulated in human naive T-
cells after stimulation [26]. Therefore, it is questionable whether it
is possible to distinguish between true TREG and recently
stimulated T-cells solely by combined staining for CD25 and
FOXP3. Nevertheless, the mainstay for quantification of TREG in
the majority of clinical studies has been the enumeration of
FOXP3+ T-cells with or without inclusion of CD25 via FCM
[5,18]. Due to the lack of a consensus staining panel for TREG,
published studies have used different markers and gating strategies
for the quantification of TREG, making comparisons between the
studies challenging.
Analyzing the epigenetic status of the FOXP3 locus using
methylation specific PCR might be a significant step towards
improved quantification of TREG. Within the FOXP3 locus exist
at least three highly conserved CpG motifs which control FOXP3
expression and are subject to epigenetic modification [27]. One of
them, the TSDR (TREG cell specific demethylation region) shows
complete and very specific demethylation in TREG [28,29].
Neither in vitro (stimulation with TGFß) generated induced TREG
(iTREG) expressing FOXP3 nor any other immune cells have a
complete demethylated TSDR [29]. This is consistent with data
showing that in vitro generated TREG display an unstable FOXP3
expression and suppressive potential [28,30]. In contrast, TREG
which are induced in vivo by delivery of antigen under tolerogenic
conditions show stable long term FOXP3 expression and
suppressive potential along with complete demethylation of the
TSDR [30]. In summary, the methylation status of the TSDR
controls the stability and longevity of FOXP3 expression and is
responsible for imprinting of a long lasting suppressive TREG-
phenotype [27]. It is thus possible to quantify the amount of TREG
in a mixed population of cells by determining copy number of
demethylated and methylated TSDR by quantitative PCR after
bisulfite treatment of genomic DNA. One aim of this study is to
compare how well the FCM determined changes in
CD4+CD25+FOXP3+ T-cells translate into changes of T-cells
which have a long lasting TREG suppressive phenotype due to
epigenetic modification of the FOXP3 locus.
With Microarray technology becoming more and more
widespread, whole genome transcriptome profiling of PBL and
peripheral blood mononuclear cells have been reported to be a
potential biomarker surrogate for several medical conditions,
including mRCC [31,32]. In this study we also examined how
changes in immune cell subsets translate into changes seen in the
PBL gene expression profile and to explore if this approach could
be useful for monitoring immune-regulatory pathways during
immunotherapy. RNA from patient PBL samples before (n = 17)
and after therapy (n = 13) as well as from PBL of controls (n = 9)
was hybridized to Affymetrix GeneChip Human Gene 1.0 ST
Arrays. The analysis revealed significant enrichment of gene sets
and pathways associated with inflammation and counter-regula-
tion in the peripheral blood of mRCC patients compared to
healthy controls.
Materials and Methods
Ethics Statement
Protocol D0238 (Phase II Clinical Trial with IL-2, IFN-a2a and
autologous dendritic cell (DC) tumor vaccination) and Leukaphe-
resis Protocol D9726 were approved by the Dartmouth College
Committee for the Protection of Human Subjects (CPHS).
Patients & Treatment Protocol
As previously reported [23], eligible patients with metastatic
RCC were treated on a phase II protocol consisting of IL-2
(Chiron, Inc. CA) administered by continuous infusion at a dose of
186106 IU/M2 for 120 hours. IFN-a 2a (6 MIU, Hofman La
Roche, Nutley NJ) was given subcutaneously every other day for 3
doses with the start of each of 5 cycles. DC vaccine (16107
autologous tumor lysate loaded DCs in 1 ml Lactated Ringer’s
Solution) was given intra-nodally under ultrasound guidance on
the day prior to starting a cycle of IL-2/IFN-a 2a.
Peripheral blood lymphocyte (PBL) isolation
PBLs were isolated from 18 patients with mRCC and 12 healthy
donors (HD). Pre-treatment PBLs from mRCC patients were
isolated 9 days before administration of the first treatment. The
second isolation (post-treatment) took place 14 days after
completion of the 2 induction cycles (33 days from start of
therapy). We obtained 12 older healthy donors (mean age 48
years) who signed IRB-approved consent and underwent leuka-
pheresis. Isolation of PBLs was achieved by fractionation of
pheresis product on an ELUTRAH Cell Separation System
(Gambro BCT, Lakewood, CA). Elutriated PBLs were washed
and cryopreserved in 90% autologous serum and 10% DMSO
until use.
Microarrays and RT-PCR
Total RNA was isolated from PBLs using RNAeasy kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions.
Biotin-labeled cDNA generated from 5.5 mg of total RNA from
PBLs of 17 patients pre-treatment, 13 patients post- treatment,
TREG & Associated Pathways in mRCC Patients
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and 9 healthy donors was hybridized to the GeneChipH Human
Gene 1.0 ST Arrays. Arrays were scanned on an Affymetrix
GeneChip Scanner 3000. Microarrays were analyzed using R and
Bioconductor [33]. Quality control was performed using Array-
QualityMetrics [34], and arrays were preprocessed with RMA
[35]. Differential expression was calculated using LIMMA
package with Benjamini & Hochberg multiple testing adjustment.
The GSEA algorithm and software has been described elsewhere
[36]. For hierarchical clustering and PCA, probesets with an
interquartile range .1.8 were selected (n = 1746). Microarray
analysis and description was carried out according to Minimum
Information About a Microarray Experiment (MIAME) guide-
lines. The dataset has been deposited in NCBI’s Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE34465) and is accessible through GEO Series
accession number GSE34465.
FCM Staining
Fluorochrome conjugated anti-human antibodies were pur-
chased from the indicated suppliers. CD3, CD4, CD8, CD45RA,
CD25 from Beckman Coulter (Fullerton, CA): GITR and, CTLA-
4 from BD Pharmingen (San Jose, CA). Intra-nuclear FOXP3-
Staining was carried out with the Biolegend FOXP3-Kit (San
Diego, CA) according to manufacturer’s instructions. All samples
were acquired on a FACS Canto (Becton Dickinson, San Jose, CA)
and analyzed with FlowJo software (Tree Star Inc. Ashland, OR).
To determine cells positive for respective markers, we set the gates
at the ,1% level of the respective isotype controls with
appropriate FMO (fluorescence minus one) staining combinations.
Definition of FCM gates
Our FCM data is from multi-parameter staining of PBL samples
with a combination of CD3, CD4, CD25 and intra-nuclear
FOXP3. For comparisons to the PCR data (see below) we define
TREG based on two gating strategies relevant to the published
TREG data from human immunotherapy trials. The gating
strategies employed for the TREG are shown in Supplementary
Fig S5. Lymphocytes are pregated on CD3+CD4+ T-helper cells.
The FOXP3+ events within the CD3+CD4+ population are
defined as single positive regulatory T-cells and subsequently
referred to as SP-TREG (SP-TREG=CD3
+CD4+FOXP3+). The
CD25+FOXP3+ events within the T–helper cell population are
defined as double positive regulatory T-cells and will be called
DP-TREG (DP-TREG=CD3
+CD4+CD25+FOXP3+). The
FCM determined amount of TREG is presented as a percentage
with a numerator of SP- or DP-TREG, and a denominator of the
total lymphocytes (PBL) or the CD3+ T-cell population. These
proportions are compared to the %TSDR of total lymphocytes or
%TSDR of CD3-T-cells as determined by methylation specific
PCR. The absolute number of Tregs were quantified by a
complete blood count performed the day of the elutriation of the
PBL. Absolute Treg numbers were calculated by multiplying the
proportion of DP-TREG/PBL as quantified by FCM with the
absolute lymphocyte count/ul from the blood count. For analysis
of the surface markers GITR, CTLA-4, CCR7 and CD45
isoforms cells were pregated on lymphocytes and then 1–2% of
these cells which were CD4+ and had the highest expression of
CD25 were selected for analysis. This gating strategy resulted in a
subset of cells that was nearly 100% FOXP3+ T-cells (Supple-
mentary Fig S1A). This population will be subsequently referred to
as CD4+CD25high T-cells. The gating strategies employed are
shown in Supplementary Fig S6.
Methylation specific Real Time-PCR for FOXP3 and CD3
Bisulfite-conversion was performed applying the EpiTect
Bisulfite Kit (Qiagen) using 1–2 ug of genomic DNA and following
the suppliers’ recommendations. Quantification of Treg and
overall T-cells by means of epigenetic qPCR analysis was carried
out as described previously [37,38].
TREG functional assay
The suppression assay was carried out as previously described
[39]. Briefly, the CD4CD25high fraction and CD4CD252/low
responder T-cells were isolated from PBL using the TREG Isolation
Kit from Miltenyi Biotec (Auburn, CA). CD4+ T cells were
negatively isolated. CD4+CD25high T-cells were isolated from the
CD4+ cells by direct labelling with anti-CD25 microbeads
(Miltenyi Biotec) followed by separation into CD25high TREG
(.95% purity) and a CD252/low fraction (responder cells). T Cell
Activation/Expansion Beads (Miltenyi Biotec) were prepared
according to manufacturer’s instructions. 2.56104 CD4+
CD252/low responder T cells were combined with varying
numbers of CD4+CD25high TREG cells and stimulated with
50,000 T Cell Activation/Expansion Beads per well then cultured
in triplicate for 5 days at 37u. On day 5, cultures were pulsed with
[3H] Thymidine (Perkin-Elmer, Boston, MA) for the last 16 to
18 hours of culture, harvested, and incorporated radioactivity
measured.
% Suppression was calculated as:
Suppression (%)~
1{
cpm(observed)
cpm( exp ected)
 
|100%~
1{
cpm(TregzTresp)
cpm(Treg)zcpm(Tresp)
 
|100%
Statistical Analysis
Statistical analysis and visualization was done using R and
SigmaStat Software. Data are expressed as mean and standard
deviation (SD) for absolute numbers and percentage and depicted
as scatter plots with the arithmetic mean indicated as a line, or as
standard Box and Whiskers Plots. These plots indicate the 25th
and 75th percentile (bottom and top box edges), median value (line
in box) and the low and high values (error bars). Statistical analysis
was performed by testing for normality and equal variance and
using Student’s t test to assess differences between the different
study groups. Where data did not have equal variance, t-test with
Welshs correction was used. P#0.05 was considered significant.
Results
Clinical results
The clinical results of the study have been previously published
[23]. Briefly, eighteen patients with advanced metastatic mRCC
(13 males, 5 females) were enrolled in the study. All patients
received up to 5 cycles intranodal vaccination with autologous
tumor lysate pulsed dendritic cells combined with high dose IL-2
and IFN-alpha. The patient characteristics and clinical outcomes
are summarized in Supplementary table 1. Overall objective
clinical response rate was 44% with three long lasting complete
responses.
TREG & Associated Pathways in mRCC Patients
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FCM analysis of healthy donor and pre and post-
treatment patient TREG populations
Flow cytometry analysis confirmed that patients with mRCC
had significantly higher absolute number of DP-TREG (DP-
TREG=CD3
+CD4+CD25+FOXP3+) in their peripheral blood
than the 12 healthy donors that were available for the analysis
(HD 16610 cells/ml vsmRCC 31615 cells/ml; p,0.01. Fig. 1A).
The proportion of DP-TREG in both the total PBL and in the T-
cell compartment was significantly elevated in mRCC-patients
(%DP TREG of PBL: HD 0.8160.48% vs mRCC 1.9460.96%
p,0.001, and %DP TREG of CD3+: HD 1.3060.69% vs mRCC
2.7461.16% p,0.001 Fig. 1B), corroborating a disease effect on
this cell population.
In order to determine a treatment effect in our patient
population, we compared levels of DP-TREG before therapy
(Pre) and 14 days after completion of the two induction cycles
(Post). We observed a significant increase of TREG absolute
numbers in the blood post treatment (Pre 30615 cells/ml vs Post
1506102 cells/ml; p,0.001, Fig. 2A). The frequency of TREG
cells within the total lymphocyte and within the CD3+ T-cell
compartment increased significantly, showing that the population
of DP-TREG was expanded relative to other immune (effector)
cells: (%DP-TREG of PBL: Pre 1.961.0 vs Post 4.763.1
Figure 1. nTREGs are increased in the peripheral blood of RCC patients. (A) Absolute numbers (HD= 12, mRCC= 15, for patients #3, #6 and
#18 a complete blood count from the day of the elutriation was not available) and (B) frequencies of TREG in the circulation of HD (n= 12) and
patients with mRCC (n= 17, all but patient #15).
doi:10.1371/journal.pone.0046600.g001
Figure 2. Frequencies and absolute numbers of TREG in the circulation of patients before therapy (Pre) and 14 days after the
completion of the two induction cycles (Post) (n =14, all but patient#3,6,15,18). Pre and post of each individual patient are connected by
a line. Red lines indicate complete responders. (A) absolute TREG numbers per ul blood, (B) proportion of DP-TREG within the PBL and (C) within the
CD3+ compartment.
doi:10.1371/journal.pone.0046600.g002
TREG & Associated Pathways in mRCC Patients
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p= 0.002, Fig. 2B and %DP-TREG of CD3
+: Pre 2.761.2 vs Post
7.265.0 p= 0.003; Fig. 2C). Thus, the frequencies of circulating
DP-TREG had on average almost tripled after two cycles of IL-2
based immune therapy.
Patients were then divided into responders (complete: CR=3
and partial response: PR=5) and non-responders (stable disease:
SD=7 and progressive disease: PD=3) based on National Cancer
Institute’s Response Evaluation Criteria in Solid Tumors. Pre-
treatment, no statistically significant differences could be found in
the numbers and proportions of DP-TREG in these two groups.
However, absolute numbers and frequencies of DP-TREG post
treatment were significantly higher in non-responders (NR) than in
responding patients (R) (absolute numbers: NR 227±115/ml vs R
93±31/ml p = 0.04, Fig. 3A; %DP-TREG of PBL: NR 7.0±2.8 vs
R 2.7±1.0 p= 0.001, Fig. 3B and %DP-TREG of CD3: NR
10.1±5.5 vs R 4.4±1.6 p= 0.015, Fig. 3C). Strikingly, patients
achieving complete and durable remissions showed the least
expansion, or even a reduction of the proportion of DP-TREG
(marked in red in Fig. 2A–C). Analysis of SP-TREG (SP-
TREG=CD3
+CD4+FOXP3+) populations in responders and
non-responders revealed differences for both baseline and post
therapy comparisons. Responders had a significantly lower
proportion of SP-TREG for both timepoints (%SP-TREG of PBL:
Pre: NR 5.4±1.6 vs R 3.5±1.0 p= 0.009 and Post: NR
Figure 3. Box and Whiskers Plots of the absolute TREG number for responders and non-responders pre and post therapy (A). Comparison of
proportions of DP-TREG of PBL and CD3
+ in the circulation of responders and nonresponders Pre and Post-treatment, respectively (B) & (C). Proportion
of SP-TREG/PBL for R and NR pre and post therapy (D). Included patients: R PRE and POST: #2,4,7–9,12,16,17; NR PRE:#1,3,5,6,10,11,13,14,18; NRPOST:
#1,5,10,11,13–15.
doi:10.1371/journal.pone.0046600.g003
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13.0±4.4 vs R 5.0±1.8 p,0.001, Fig. 3D). Lowering the gating
cutoff for CD25 led to results approaching those of the SP-gating
strategy for the pre treatment comparison between responders and
non-responders (data not shown). This illustrates that setting the
gates on continuous markers such as CD25 can be difficult even
with proper isotype controls (Supplementary Fig. 1A) and may
lead to different conclusions based on the same dataset.
We further characterized the TREG cell population in the
patients by evaluating the expression of CTLA-4, GITR, CCR7
and CD45RA within the CD4+CD25high compartment (Supple-
mentary Fig S2A). CTLA-4 could be found consistently on the
surface of about 80% of the CD4CD25high population of healthy
donors as well as in patients before and after therapy. GITR,
however, was only detected on a minor fraction of CD4CD25high
cells. Most CD4CD25high were found to belong to the central
memory subtype in both patients and healthy donors (%CCR7+
CD45RA2:Pt 63.8616.4 vs HD 56.6633.4; ns; Supplementary
Fig S2B). About 10% were naive TREG (%CCR7
+ CD45RA+:Pt
9.866.8 vs HD 7.265.6; ns). In summary, no significant
differences in the surface phenotype of CD4+CD25high T-cells in
untreated mRCC patients and healthy donors could be detected
using these markers.
In further analysis, the expression of CTLA-4 and GITR did
not significantly differ between pre and post-therapy TREG.
However, within the CD4+CD25high compartment we detected a
significant treatment related shift towards naive (CD45RA+
CCR7+) T-cells (Pre 6.3±5.7% vs Post 24.8±11.37%
p,0.001; Supplementary Fig S2B) at the cost of the central
memory (CD45RA2CCR7+) CD4+CD25high T-cells. In analysis
of response related differences, the expression of CTLA-4 and
GITR and the distribution between memory and naive
CD4+CD25high T-cells did not differ between CD4+CD25high T-
cells from these two groups (data not shown), suggesting that the
difference between responders and non-responders are different
frequencies of TREG, not different phenotypes of the regulatory
cell population.
Functional suppressive ability of patient TREG cells
The suppressive ability of enriched CD4+CD25high T-cells was
analyzed for six patients pre and post-treatment cells, as well as for
4 healthy donor controls. TREG -Suppression assays (Supplemen-
tary Fig S3) revealed that the CD4+CD25high T-cells from mRCC
patients were functional and efficiently inhibited proliferation of
CD4+CD252 responder cells with no significant difference from
the CD4+CD25high T-cells of healthy donors.
Relationship of methylation specific PCR results and FCM
data
In the PCR method TREG were quantified by determining the
proportion of demethylated TSDR alleles compared to methylated
TSDR alleles in the patient PBL samples. Genomic DNA was
treated with bisulfite and the differently methylated TSDR were
amplified with methylation specific primers in a quantitative PCR
[38]. Twelve patient samples (6 responders, 6 non-responders)
were available for pre and post-treatment comparison. For
determination of the frequency of CD3+ T- cells within the
sample a similar methylation specific PCR was performed
interrogating the methylation state of the CD3 locus. Results of
the PCR analysis are reported as % dTSDR/PBL and %
dTSDR/CD3+ (d = demethylated) reflecting the proportion of
TREG of all cells in the elutriated sample (lymphocytes) and the
proportion of TREG within the CD3
+ T-cell compartment,
respectively. The latter was obtained by normalizing the number
of demethylated TSDR alleles to the number of demethylated
CD3 alleles.
The PCR results corroborated the FCM findings for a
treatment effect: post-treatment samples had an average of more
than 2 fold the TREG of the pre-treatment samples for both the
lymphocyte and CD3 PCR quantification (% dTSDR/PBL: Pre
4.961.8% vs Post 10.165.2% p=0.006, Fig. 4A; % dTSDR/
CD3+: Pre 6.362% vs Post 13.866.8% p=0.002; Fig. 4B).
Only two patients (#4 and #8) showed a reduction in the absolute
number of methylated TSDR alleles, and strikingly, both were
complete responders. The third CR (#17) had the lowest absolute
number of dTSDR alleles at baseline and showed a moderate
increase after the therapy (Fig. 4A). A fourth patient (#16) who
demonstrated stable dTSDR/PBL levels exhibited a near com-
plete response, however the response was short-lived (TTP 7
months).
Figure 4. Methylation specific PCR for 12 patients with pre and post samples available (#1, 2,4,5,7–10,13,14,16,17). (A) Treatment
related results of (% dTSDR/PBL and (B) %dTSDR/CD3+: % demethylated alleles of TREG cell specific demethylation region within the lymphocyte and T
cell population respectively. Red lines indicate complete responders (C) Response related results of methylation specific PCR for pre and post-therapy
TREG (R = 6, NR= 6).
doi:10.1371/journal.pone.0046600.g004
TREG & Associated Pathways in mRCC Patients
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Overall, responding patients showed a lower amount of dTSDR
in their samples after therapy. However, it failed to reach statistical
significance due to limited numbers of patients available for the
analysis (% dTSDR of PBL: R Post 8.463.5% vs NR Post
12.666.5 p= 0.25, Fig. 4C). The PCR based method generally
reported a higher proportion of TREG cells than the respective
TREG proportions as determined by FCM (Fig. 5A). Particularly
FCM gating on DP-TREG cells seemed to underestimate the
proportion of regulatory T-cells as quantified by PCR by a factor
of more than 2. Gating on the SP-TREG -cells led to numerical
results which matched the values obtained by PCR more closely
(% dTSDR 7.564.5; SP-TREG 6.163.7; % DP-TREG 3.262.6;
n = 24; Fig. 5A). This suggests that by conservative FCM gating on
the CD25+FOXP3+ DP-TREG population, a significant portion of
functionally stable regulatory T-cells may not be taken into
account.
Linear regression revealed an overall high degree of correlation
between all the FCM gating strategies and the respective PCR
results (Fig. 5 B–F). Quantification of CD3+ T-cells within the
lymphocyte population by methylation specific PCR-analysis of
the CD3-locus compared to the proportion of CD3+ by FCM
achieved a correlation coefficient of 0.91 (Fig. 5D). Linear
regression between the PCR results and % DP-TREG resulted in
regression lines substantially above the id-line (Fig. 5 E–F), again
indicating that FCM in our hands, underestimated the proportion
of TREG within a mixed population of cells. Despite the differences
in absolute values for the two methods, the FCM results from the
DP-TREG gating (Fig. 5 E–F) were better correlated with the PCR
results than FCM gating on SP-TREG (Fig. 5 B–C). In summary,
gating on the CD4+CD25+FOXP3+ DP-TREG led to quantifica-
tion of TREG different in absolute value but with a high prediction
confidence for the relative proportion of stably suppressive
regulatory T-cells as quantified by TSDR-PCR.
Analysis of enrichment of gene sets associated with
immune regulatory pathways
RNA from patient samples pre (n = 17; #1–14 and #16–18)
and post-therapy (n = 13,#1,#2,#4,#5,#8–14,#16,#17) as well
as nine available controls was processed and hybridized to
Affymetrix GeneChip Human Gene 1.0 ST Arrays. For unsuper-
vised analysis, 1700 probesets with the largest variance were
selected. Hierarchical clustering and principle components anal-
ysis (Fig. 6A and B) demonstrated that all HD but one formed a
distinct cluster clearly separated from the patient samples. An
obvious clustering of the patient samples based on grouping by the
treatment related variables Pre, Post or Responder, Non-
responder was not observed (Supplementary Fig S4). This result
Figure 5. TREG estimates obtained by methylation specific PCR and two FCM gating strategies for 24 samples (12 pre, 12 post). (A)
Measurements for the same sample are connected by a line. (B–F) Linear regression between the results of methylation specific PCR for the TSDR
locus and defined FCM populations. Solid black: regression line; Black dotted: 95% confidence interval of the regression line; Red dotted: Id-line with a
slope of 1.0 and an intercept of 0. In subscript numerical results of the linear model.
doi:10.1371/journal.pone.0046600.g005
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was reproducible when the variance based gene filter (interquartile
range, IQR) was set higher to select fewer genes or lower for more
genes (data not shown).
We focused our analysis on pathways commonly associated with
TREG and immune-regulation, using Gene Set Enrichment
Analysis [36]. From more than 3000 curated gene sets stored in
the MySig Database (C2.All.V3.0/Broad Institute, MIT) we
searched for gene sets that matched one of the following terms:
regulatory, FOXP3, CTLA-4, TGF-ß, SMAD, IL2 or T-cell
signal transduction. This selection was done to increase test power
and reduce irrelevant discoveries by testing thousands of gene sets
stored in the database not related to the immune system. A list
consisting of 16 gene sets matching these terms (Supplementary
table 2) was compiled and used to test for enrichment in HD vs
pre-treatment patient phenotypes. Significantly enriched in
mRCC patients (Fig. 7, Supplementary Table 3) were the Biocarta
TGF-ß pathway (rank 1, p = 0.013, FDR=0.17), both FOXP3
target gene sets from Marson et al (Ref; rank 2 and 3, p = 0.04,
FDR=0.14 and 0.17) and the Biocarta IL2R pathway (rank 4,
p = 0.03, FDR=0.137). Also enriched were the Biocarta CTLA-4
inhibitory pathway (rank 7, p= 0.04, FDR=0.133) and TCR
pathway (rank 6, p = 0.04, FDR=0.013). Similar comparisons of
pre vs post and responders vs non-responders, applying the
selected gene sets, showed no relevant differences related to
treatment or response to treatment.
An unsupervised approach testing all available gene sets
(n<3000) found the previously mentioned immune regulatory
signatures among the top 50 of all tested gene sets, with TCR and
FoxP3 ranking 2 and 6, respectively. Furthermore, gene sets
related to mTOR-activation, cell cycling and receptor tyrosine
kinase signaling were found to be highly enriched in the mRCC
patient samples. Again, no gene sets or individual genes were
robustly differentially regulated for Pre vs Post or R vs NR.
Discussion
In recent years it has become evident that tumors actively evade
eradication by the immune system by several mechanisms. TREG
are a notable one of these, and are now considered a major
obstacle towards successful immunotherapy. Several studies have
addressed the role of TREG in the clinical setting of cytokine
therapy, particularly in melanoma and mRCC [5,18,21,40]. In
this analysis, we determined the impact of combined vaccination
and high dose cytokine therapy on number and function of TREG
cells in vivo employing three different methodological approaches
currently available for immune monitoring of clinical trial samples.
Our study confirms previous reports that mRCC patients have
higher numbers of circulating TREG than healthy controls. We
demonstrated that the expanded TREG cells in mRCC patients are
functional and further characterized them as similar to those in
healthy individuals with regard to expression of CTLA-4 and
GITR, as well as naive and memory phenotype.
DC-vaccination combined with high dose IL-2 and IFNa
increased the absolute number and percentage of circulating TREG
significantly. In the course of therapy responding patients
exhibited a significantly smaller expansion of their TREG cells.
The group of patients enrolled in this trial were mainly in the
intermediate MSKCC category. This homogeneity of patient stage
should limit a possible influence of the overall tumor burden on
the outcomes observed. Our results corroborate previous findings
of at least three other groups. Jensen et al. looked for FOXP3+ cells
in mRCC tumor core biopsies in patients undergoing IL-2 therapy
Figure 6. Ward-dendrogramm obtained by unsupervised hierarchical clustering of patients and control (HD) samples using Manhattan distance (A),
Principle Components Analysis. Encircled are the healthy controls with one outlier (arrow) (B). Each point represents one microarray sample. The plot
was obtained by projecting the samples from the feature space onto the first three principle components, which cover about 50% of the total
variance in the data.
doi:10.1371/journal.pone.0046600.g006
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[40]. They showed that intra-tumoral FOXP3+ regulatory
immune cells significantly increase during IL-2-based immuno-
therapy. Patients with high expansion of FOXP3+ cells in biopsy
specimens had a significantly worse prognosis than patients with
only a moderate rise in the FOXP3+ cell numbers. Cesana et al.
reported a poor outcome for patients with a very high number of
TREG in their blood after IL-2 based immunotherapy as well [18].
Rosenberg et al evaluated the outcome from four clinical trials
employing adoptive T-cell transfer combined with various
conditioning regimes and found that the levels of endogenous
CD4+ FoxP3+ T-cells are inversely correlated with outcome [5].
Some studies have reported that higher numbers of TREG in the
blood at the beginning of therapy influenced the outcome [41].
Although we found significantly lower pre-treatment TREG
proportions in responding patients based on the SP- TREG FCM
gating (Fig. 3D), it was not statistically confirmed based on the DP-
TREG FCM gating strategy or the PCR method. Notably, in our
study the patient who had the highest pre-treatment TREG
proportion of all the patients (#8) exhibited a long lasting
complete remission. Strikingly, this was the only patient who had a
significant reduction in the proportion of TREG as determined by
FCM and PCR upon therapy, highlighting that minimizing the
level of TREG expansion under immunotherapy might be more
important for objective clinical responses than the pre-treatment
TREG levels. Overall, our data support the use of quantifying
TREG as a surrogate marker for monitoring immunotherapy in
patients, and highlight the prognostic importance of TREG
expansion under immunotherapy.
In light of these results, methods that allow reliable and
consistent measurement of stable suppressive TREG across studies
are essential. The recently developed methylation specific PCR-
based method [38] to quantify TREG by determining the amount
of demethylated (TREG specific) and methylated (all other immune
cells) TSDR sequences in a sample may help achieve this goal. We
consistently found a lower proportion of DP-TREG by FCM
compared to the TSDR PCR method, which likely resulted from
the presence of a significant amount of true TREG in the CD25
low/2
population which was excluded by conservative CD25+ FCM
gating, but detected by the PCR method. Gating only on FOXP3+
T-cells (SP-TREG), as for example used by Rosenberg et al [5],
results in FCM TREG values that match the results of the PCR
better, but the ‘‘noise’’ introduced by inclusion of recently activated
FOXP3+ T-cells which are not true TREG is reflected in a lower
correlation of SP-TREG flow cytometry and PCR results. However,
even though Rosenberg et al found, with a far larger number of
patients than our study, a clear association between clinical response
Figure 7. Gene Set Enrichment Analysis for 9 healthy donors (grey) and 17 mRCC samples pre-treatment (yellow). Shown are
representative regulatory pathways that were ranked among the top 50 gene sets upregulated in the mRCC samples. (A) Marson FOXP3 target genes
(p = 0.03), (B) IL2R pathway (p = 0.03), (C) TGFB pathway (p = 0.01).
doi:10.1371/journal.pone.0046600.g007
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and TREG levels, they also found that the levels of TREG had a poor
prediction confidence for clinical outcome using logistic multivar-
iable regression [5]. The authors concluded that TREG levels are not
useful as significant predictor of response to immunotherapy [5].
However, in this study we show that gating on CD4+FoxP3+ cells
has a lower prediction confidence for the true levels of TREG
as gating on CD4+CD25+FoxP3+. The noise inherent to the
CD4FoxP3 method might have contributed to the lack of predictive
power found by Rosenberg et al. It is therefore neccessary to
establish a more precise and reproducible measurement of TREG
before final conclusions can be drawn whether TREG can serve as a
useful biomarker or not.
Most studies to date have only reported FCM results for TREG
quantification, which brings into question the contribution of (IL-
2) activated T-cells and transiently induced TREG to these results,
as some of these cells express CD25 and FOXP3 without actually
being stable functional TREG [27]. The methylation specific PCR
results from our study show that IL-2 based immunotherapy leads
to a substantial expansion of T-cells with a demethylated TSDR,
i.e. TREG which have a long lasting suppressive phenotype due to
epigenetic modification of the FOXP3 locus. More substantial
expansion of TREG post- therapy in non-responding patients than
in responding patients observed within the FCM data is supported
by the PCR method results, although it does not reach statistical
significance. This can be explained by a lower patient sample
number available for PCR analysis (12 patients, Fig. 3) compared
to FCM (18 patients, Fig. 2). Whether IL-2 therapy expands the
peripheral pool of TREG or enhances thymic output, or both,
remains to be determined. Results of studies with greater patient
numbers will be needed to establish whether the epigenetic
method for TREG quantification is superior to predict patient
outcome compared to FCM based strategies. In our study,
incorporating additional FCM markers of TREG (CTLA4, GITR,
etc.) did not allow further discrimination of treatment related or
response related differences between patients. Our results support
the use of the methylation specific PCR method because it
circumvents much of the variability and subjectivity of the FCM
method of TREG quantification.
Genomewide transcriptional profiling of cell samples of patients
is being adopted as a mainstay in the search for biomarkers
predicting outcome or monitoring therapeutic response. We
applied microarray analysis to PBL patient samples and healthy
controls, and for this study focused on the impact of mRCC and
immunotherapy on pathways associated with TREG and immu-
nosuppressive cytokines using GSEA. Analyzing gene sets rather
than single (‘‘significant’’) genes has been proven to be a valuable
tool to compare clinical microarray datasets, due to the high
variation inherent in patient derived expression profiles, leading to
lack of reproducibility between studies [36]. In GSEA the overall
behaviour of groups of biologically related genes is assessed
without arbitrary cut offs, which is more sensitive and less error
prone than the single-significant gene approach [42].
In our study, expression profiles of mRCC patients were
globally different from the healthy donors assigning them to a
distinct cluster in PCA and unsupervised hierarchical clustering.
This makes it possible to assign a sample to the patient or control
cohort based on the gene expression signature. We queried more
than 3000 gene sets available from public databases and found
gene sets related to cell activation, cell cycling and receptor
tyrosine kinase signaling were highly enriched in the mRCC
patient samples, suggesting a state of enhanced activation of the
immune system. A priori defined gene sets associated with
regulatory T-cells comprising the FOXP3, TGF-ß, IL-2 and
CTLA-4 pathways were highly upregulated in the patient samples.
In contrast to the large difference between healthy donors and
mRCC patients, we failed to detect robustly differentially
regulated genes or gene sets between Pre and Post therapy nor
between responding and non-responding patients using the
preselected immune-regulatory gene sets. A possible explanation
why the changes in the TREG compartment during therapy and
between R and NR did not translate into readily dectectable
changes in the expression profiles is that TREG comprise a
relatively small subset of immune cells. It is highly likely that
treatment related changes in other immune cell subsets e.g. NK
cells and T-cells [23], that make up a considerably larger fraction
of PBL, mask the changes occuring within the TREG population.
Furthermore, the considerable variance in the expression profiles
of patients from different genetic background and clinical course
as well as limitations in sample size restricted the power to detect
possible differences. For a more thorough analysis and discussion
of this dataset see Wolf et al. 2012 [43]. Larger studies across
different cancer types are needed to clarify whether ‘‘cancer type
specific’’ cell expression profiles do exist in PBMC and if they are
useful for screening or monitoring (immune) therapy.
In the clinic, cytokine therapy treatment for mRCC patients has
been replaced by small molecule inhibitors or antibodies like
Sorafenib/Sunitib which offer a higher response rate and less
adverse effects. However, these treatments fail to induce long
lasting (complete) remissions, which have been observed in a
limited number of patients treated with immunotherapy. Com-
bined multi-modality treatment strategies for cancer that incor-
porate ways to minimize TREG and other mechanisms of
suppression, and that elicit tumor specific immunity using
vaccines, cytokines or adoptive cellular approaches remain an
attractive therapeutic approach. Monitoring treatment related
changes in TREG in peripheral blood and tumor tissue will
continue to be important for a wide range of diseases and
treatment strategies, and ‘‘standardization’’ of TREG quantification
would be beneficial.
Supporting Information
Figure S1 The FCM plot, pre-gated on lymphocytes, shows that
within the CD25high population nearly 100% of the cells are also
FoxP3+(A), Linear regression between CD4+CD25high T-cells and
CD4+CD25+FOXP3+ DP-TREG both measured by Flow Cytom-
etry reveals a correlation of R= 0.91 between the two different
populations(B).
(TIF)
Figure S2 Expression of surface molecules within the
CD4+CD25high compartment. (A) Expression of CTLA-4, and
GITR did not differ between healthy controls and mRCC
patients. (B) Distribution of T-cells belonging to central memory,
effector memory or naive phenotype within the CD4+CD25high T-
Cell compartment in HD and mRCC patients before and after
therapy.
(TIF)
Figure S3 TREG suppression assay. CD4
+CD252 T-cells were
mixed with CD4+CD25high regulatory T-cells and stimulated with
T-cell activation/expansion beads. Proliferation was measured by
[3H]-Thymidine incorporation. Patients with pre and post samples
available for the assay were: #1,2,5,9,13,16.
(TIF)
Figure S4 Principle components analysis of the patients’
microarray samples with respect to the variables Non-responder,
Responder, Pre and Post
(TIF)
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Figure S5 FCM gating strategies for (A) DP- and (B) SP-TREG as
described in materials and methods. CD3 plot is pre-gated on
lymphocytes by scatter.
(TIF)
Figure S6 FCM gating strategies for CTLA4: isotype control in
gray, CTLA4 Ab solid black line(A), CCR7/CD45RA T memory
cell gating strategy(B). CD3 plot is pre-gated on lymphocytes by
scatter.
(TIF)
Table S1 Clinical data for enrolled patients (n = 18). Abbrevi-
ations: M=male, F = female, cc = clear cell, s = sarcomatoid,
m=medullary, LN= lymph node, MSKCI/UISS=Memorial
Sloan Kettering Cancer Institute/UCLA Integrated Staging
System, L=Low, Int = Intermediate
(DOCX)
Table S2 MSigDB Genesets associated with FoxP3, CTLA-4
and TGFß.
(DOCX)
Table S3 Gene Sets enriched in PBL of mRCC patients at an
FDR,0.2.
(DOCX)
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